T. Rowe Price Associates
NERV icon

T. Rowe Price Associates’s Minerva Neurosciences NERV Stock Holding History

T. Rowe Price Associates’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Buy
+27,921
New +$151K ﹤0.01% 3069
2021
Q4 		– Sell
-7,038
Closed -$98K – 3026
2021
Q3 		$98K Hold
7,038
– – ﹤0.01% 2851
2021
Q2 		$131K Sell
7,038
-338
-5% -$7.28K ﹤0.01% 2808
2021
Q1 		$172K Buy
+7,376
New +$184K ﹤0.01% 2722
2020
Q2 		– Sell
-120,076
Closed -$5.78M – 2526
2020
Q1 		$5.78M Sell
120,076
-34,523
-22% -$2.08M ﹤0.01% 1317
2019
Q4 		$8.79M Sell
154,599
-6,143
-4% -$271K ﹤0.01% 1332
2019
Q3 		$9.97M Sell
160,742
-24,483
-13% -$1.39M ﹤0.01% 1294
2019
Q2 		$8.34M Sell
185,225
-11,506
-6% -$576K ﹤0.01% 1345
2019
Q1 		$12.4M Buy
196,731
+9,650
+5% +$580K ﹤0.01% 1288
2018
Q4 		$10.1M Sell
187,081
-28
-0% -$2.05K ﹤0.01% 1302
2018
Q3 		$18.8M Sell
187,109
-4,015
-2% -$302K ﹤0.01% 1251
2018
Q2 		$12.6M Sell
191,124
-17,621
-8% -$1.07M ﹤0.01% 1303
2018
Q1 		$10.4M Buy
208,745
+231
+0.1% +$11.1K ﹤0.01% 1325
2017
Q4 		$10.1M Buy
208,514
+175
+0.1% +$8.68K ﹤0.01% 1342
2017
Q3 		$12.7M Sell
208,339
-29,918
-13% -$1.72M ﹤0.01% 1300
2017
Q2 		$16.9M Buy
238,257
+162,089
+213% +$10.5M ﹤0.01% 1225
2017
Q1 		$4.94M Buy
76,168
+1,049
+1% +$81.5K ﹤0.01% 1431
2016
Q4 		$7.06M Sell
75,119
-4,937
-6% -$504K ﹤0.01% 1378
2016
Q3 		$9.04M Buy
+80,056
New +$7.77M ﹤0.01% 1336

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's NERV Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Minerva Neurosciences (NERV) in Q2 2026: 27,921 shares worth $155K. The stake represents ﹤0.01% of the portfolio and ranks #3069 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in NERV as recently as Q3 2021.

T. Rowe Price Associates first reported a position in NERV in Q3 2016 and has held it in 19 quarters since. The position peaked at $18.8M in Q3 2018. 61 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • T. Rowe Price Associates held 27,921 shares of Minerva Neurosciences worth $155K as of Q2 2026.
  • Minerva Neurosciences was a new T. Rowe Price Associates position in Q2 2026.
  • Minerva Neurosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3069 holding.
  • T. Rowe Price Associates first reported a position in Minerva Neurosciences in Q3 2016 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Minerva Neurosciences position peaked at $18.8M in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.